Werewolf Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Werewolf Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($16.37M) | Nov 4, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($17.98M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($17.98M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($18.09M) | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($18.09M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($18.09M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($16.67M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($17.25M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($17.25M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.19M) | May 8, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($16.19M) | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($16.19M) | Aug 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.29M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.10M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($5.10M) | Nov 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($11.98M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.98M) | May 3, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($11.98M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.94M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.59M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($15.73M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($17.54M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($17.99M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($17.12M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.96M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($17.16M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.25M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.07M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.22M) | May 3, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.54M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.97M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($15.37M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($13.80M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($10.96M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($7.45M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($6.05M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($5.07M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.89M) | Jun 10, 2021 |